As a science entrepreneur, the toughest part of progressing research to deliver meaningful impact is often securing the right funding. Identifying support in the right timeframe that allows ambitious scientific ideas to mature into transformational research programmes can be a challenge. 

The arrival of the Focused Research Organisation (FRO) model is beginning to make that challenge easier for researchers who find themselves caught between traditional academic funding and venture capital-backed commercial routes. FROs are designed to tackle scientific bottlenecks that require focused, long-term investment, multidisciplinary teams and the creation of tools, platforms or datasets that benefit an entire field. Lynne Trowbridge and I decided to dig a little deeper into the funding of this new model, exploring how UK-based FROs can chose to fund their ambitious plans.  

The Focused Research Organisation model was emerging in the United States through the work of Convergent Research (CR). At the time, however, there was no equivalent to CR in the UK.  

That changed in early 2025 when ARIA announced that Convergent Research had joined its Activation Partners programme. Together, the two organisations sought to identify and address major scientific and technological bottlenecks by launching purpose-built research organisations dedicated to ambitious research challenges.  

When applications opened for the UK FRO Founder Residency, information circulated through scientific networks and mailing lists. Selected applicants then developed and refined their concepts through a cohort-based programme designed to incubate, launch and support UK FROs. The pilot ultimately led to the launch of two new organisations in April 2026.  

Ahead of this, Bind Research arrived at the FRO model through a different route. Rather than being established through the ARIA-Convergent ecosystem, the organisation was created through the UK's Research Ventures Catalyst programme alongside philanthropic funding becoming the first UK-based FRO in February 2025. The founders realised that neither academia nor biotech offered the right environment to build large-scale datasets, create new experimental methods and generate public goods for the wider research community. The FRO model provided an attractive alternative. Gabi, Thomas, and Gogs received seed funding from the UK government to explore whether this structure would work for their science. 

For Bind Research, the ambition is to create the datasets, computational tools and experimental infrastructure necessary to understand how small molecules interact with intrinsically disordered proteins. Rather than developing a single therapeutic asset, the organisation aims to generate resources that can be used across academia and industry to unlock new approaches to drug discovery. As Gabi Heller explains:  

“Academia is often optimised for producing papers, while investors typically expect clear commercial products. Creating large-scale scientific infrastructure that benefits an entire field can be difficult to support within either framework. The FRO model bridges this gap by enabling teams to pursue ambitious missions that generate public benefit while operating with greater focus and cohesion than traditional academic collaborations.”  

Achieving this requires sustained investment and the freedom to focus on building foundational scientific capability before pursuing commercial applications.  

One of the most striking aspects of the emerging UK FRO ecosystem is that there is no single route to success. 

Funding can come through the partnership between ARIA and Convergent Research, combining long-term financial support with the operational expertise required to establish and launch a new organisation. The funding is committed for a multi-year fixed term and provides the resources needed to build the core scientific hypotheses and achieve agreed milestones.  

For Bind Research, the funding journey looked different. Support from the UK's Research Ventures Catalyst programme, philanthropic funders, and industrial partners enabled the organisation to establish itself as an independent, not-for-profit company with a five-year scientific mission. According to Heller, receiving substantial funding upfront gave the team flexibility to build specialist infrastructure, recruit world-class talent and adapt as new opportunities emerged.  

While the funding structures differ, FROs demonstrate the importance of providing ambitious scientific teams with the time, resources and organisational freedom required to tackle difficult problems that may otherwise remain unsolved.  

A number of FRO’s have now been established both in the US and in the UK. In all cases, the founders identified ambitious scientific challenges that required a new organisational model capable of supporting long-term, mission-driven research.  

Along with the leaders of all these new organisations, we too hope that Focused Research Organisations become a recognised and permanent part of the UK's research ecosystem. 

It is clear that the FRO model is not a replacement for universities or venture-backed companies, but an important complement to both. By occupying the space between academia and industry, FROs provide a mechanism for tackling ambitious scientific challenges that require sustained focus, long-term funding and the creation of public goods.  

We are sharing these stories about FROs to help demonstrate the flexibility of the model. Different scientific missions, different funding pathways and different organisational structures, can all benefit from the FRO model to bridge the gap between scientific ambition and scientific reality in the UK. Our thanks to Gabi, Gogs, Thomas and other FRO experts for taking timeout to share their insights and unique journeys with us.